Condition: Nonmuscle-invasive Bladder Cancer · Sponsor: ImmVira Pharma Co. Ltd
This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.
This description comes directly from the study's public registry record.
Jasmine Yang · 86-512-66202028 · xu.yang@immviragroup.com
Always discuss trial participation with your own doctor first.
| East Valley Urology Center | Queen Creek, Arizona, United States | Not Yet Recruiting |
| Florida Urology Partners, LLP | Tampa, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06971614